{
    "2021-01-18": [
        [
            {
                "time": "",
                "original_text": "智飞生物现5笔大宗交易 共成交49,307.04万元",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "大宗交易",
                        "成交额"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物现5笔折价大宗交易 机构买入4.93亿元",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "大宗交易",
                        "折价",
                        "机构买入"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业跨市场周报：假如市场风格切换 如何把握医药二线机会？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "市场风格切换",
                        "二线机会"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物：中国创新药是否到了国际化的拐点？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "中国创新药",
                        "国际化",
                        "拐点"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药生物：CXO景气度持续高涨 重点推荐药明康德、凯莱英等",
                "features": {
                    "keywords": [
                        "医药生物",
                        "CXO",
                        "景气度",
                        "药明康德",
                        "凯莱英"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}